CA3031251A1 - Platforms to implement signal detection metrics in adaptive response-deadline procedures - Google Patents
Platforms to implement signal detection metrics in adaptive response-deadline procedures Download PDFInfo
- Publication number
- CA3031251A1 CA3031251A1 CA3031251A CA3031251A CA3031251A1 CA 3031251 A1 CA3031251 A1 CA 3031251A1 CA 3031251 A CA3031251 A CA 3031251A CA 3031251 A CA3031251 A CA 3031251A CA 3031251 A1 CA3031251 A1 CA 3031251A1
- Authority
- CA
- Canada
- Prior art keywords
- response
- individual
- task
- interference
- user interface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 251
- 230000003044 adaptive effect Effects 0.000 title claims abstract description 40
- 238000001514 detection method Methods 0.000 title abstract description 27
- 230000004044 response Effects 0.000 claims abstract description 783
- 230000001149 cognitive effect Effects 0.000 claims abstract description 159
- 230000003993 interaction Effects 0.000 claims abstract description 45
- 238000012545 processing Methods 0.000 claims description 159
- 230000008859 change Effects 0.000 claims description 105
- 239000003814 drug Substances 0.000 claims description 74
- 229940079593 drug Drugs 0.000 claims description 72
- 238000005259 measurement Methods 0.000 claims description 55
- 239000008177 pharmaceutical agent Substances 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 44
- 230000015654 memory Effects 0.000 claims description 41
- 230000033001 locomotion Effects 0.000 claims description 37
- 238000004458 analytical method Methods 0.000 claims description 35
- 230000003935 attention Effects 0.000 claims description 34
- 238000009877 rendering Methods 0.000 claims description 31
- 238000012986 modification Methods 0.000 claims description 29
- 230000004048 modification Effects 0.000 claims description 29
- 230000006870 function Effects 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 25
- 238000009825 accumulation Methods 0.000 claims description 24
- 230000035945 sensitivity Effects 0.000 claims description 24
- 238000004448 titration Methods 0.000 claims description 22
- 230000008921 facial expression Effects 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 230000002123 temporal effect Effects 0.000 claims description 18
- 238000013542 behavioral therapy Methods 0.000 claims description 17
- 238000009223 counseling Methods 0.000 claims description 17
- 238000009792 diffusion process Methods 0.000 claims description 16
- 238000011269 treatment regimen Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 238000012544 monitoring process Methods 0.000 claims description 15
- 208000010877 cognitive disease Diseases 0.000 claims description 13
- 230000003287 optical effect Effects 0.000 claims description 13
- 238000012549 training Methods 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000005094 computer simulation Methods 0.000 claims description 11
- 230000006735 deficit Effects 0.000 claims description 11
- 230000003936 working memory Effects 0.000 claims description 11
- 208000029560 autism spectrum disease Diseases 0.000 claims description 10
- 208000024714 major depressive disease Diseases 0.000 claims description 8
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 238000013528 artificial neural network Methods 0.000 claims description 7
- 230000007659 motor function Effects 0.000 claims description 7
- 230000000626 neurodegenerative effect Effects 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 230000007787 long-term memory Effects 0.000 claims description 6
- 230000010332 selective attention Effects 0.000 claims description 6
- 230000006403 short-term memory Effects 0.000 claims description 6
- 230000002459 sustained effect Effects 0.000 claims description 6
- 230000004304 visual acuity Effects 0.000 claims description 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 238000009227 behaviour therapy Methods 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000012417 linear regression Methods 0.000 claims description 4
- 238000007477 logistic regression Methods 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 238000000513 principal component analysis Methods 0.000 claims description 4
- 238000007637 random forest analysis Methods 0.000 claims description 4
- 230000031893 sensory processing Effects 0.000 claims description 4
- 238000012706 support-vector machine Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000008133 cognitive development Effects 0.000 claims 2
- 238000011981 development test Methods 0.000 claims 2
- 230000003930 cognitive ability Effects 0.000 abstract description 22
- 230000000670 limiting effect Effects 0.000 description 72
- 230000008569 process Effects 0.000 description 26
- 238000009826 distribution Methods 0.000 description 19
- 238000004891 communication Methods 0.000 description 15
- 230000000704 physical effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 238000004590 computer program Methods 0.000 description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008449 language Effects 0.000 description 7
- 229960001344 methylphenidate Drugs 0.000 description 7
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 6
- 238000010801 machine learning Methods 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000003557 neuropsychological effect Effects 0.000 description 5
- 206010021567 Impulsive behaviour Diseases 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002582 magnetoencephalography Methods 0.000 description 3
- 238000010295 mobile communication Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000008825 perceptual sensitivity Effects 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- LDDHMLJTFXJGPI-LFPUEVJFSA-N [(3s,5r)-3,5-dimethyl-1-adamantyl]azanium;chloride Chemical compound Cl.C1C(C2)C[C@@]3(C)C[C@]1(C)CC2(N)C3 LDDHMLJTFXJGPI-LFPUEVJFSA-N 0.000 description 2
- 229950008995 aducanumab Drugs 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 229950001954 crenezumab Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 2
- 229960003135 donepezil hydrochloride Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000010344 pupil dilation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004323 rivastigmine tartrate Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000010454 slate Substances 0.000 description 2
- 229950007874 solanezumab Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000004633 cognitive health Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000010387 memory retrieval Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
- A61B5/0533—Measuring galvanic skin response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1121—Determining geometric values, e.g. centre of rotation or angular range of movement
- A61B5/1122—Determining geometric values, e.g. centre of rotation or angular range of movement of movement trajectories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/168—Evaluating attention deficit, hyperactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Physiology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Social Psychology (AREA)
- Databases & Information Systems (AREA)
- Neurosurgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Educational Technology (AREA)
- Mathematical Physics (AREA)
- Evolutionary Computation (AREA)
- Signal Processing (AREA)
- Fuzzy Systems (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364297P | 2016-07-19 | 2016-07-19 | |
| US62/364,297 | 2016-07-19 | ||
| US29/579,480 USD879133S1 (en) | 2016-09-30 | 2016-09-30 | Display screen or portion thereof with an animated graphical user interface |
| US29/579,480 | 2016-09-30 | ||
| PCT/US2017/042938 WO2018017767A1 (en) | 2016-07-19 | 2017-07-19 | Platforms to implement signal detection metrics in adaptive response-deadline procedures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3031251A1 true CA3031251A1 (en) | 2018-01-25 |
Family
ID=60992822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3031251A Pending CA3031251A1 (en) | 2016-07-19 | 2017-07-19 | Platforms to implement signal detection metrics in adaptive response-deadline procedures |
Country Status (6)
| Country | Link |
|---|---|
| JP (2) | JP7267910B2 (ko) |
| KR (1) | KR102449377B1 (ko) |
| CN (1) | CN109996485B (ko) |
| AU (1) | AU2017299614A1 (ko) |
| CA (1) | CA3031251A1 (ko) |
| WO (1) | WO2018017767A1 (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11120158B2 (en) | 2018-04-13 | 2021-09-14 | Plaid Inc. | Secure permissioning of access to user accounts, including secure distribution of aggregated user account data |
| CA3115994A1 (en) * | 2018-10-15 | 2020-04-23 | Akili Interactive Labs, Inc. | Cognitive platform for deriving effort metric for optimizing cognitive treatment |
| CN109635917B (zh) * | 2018-10-17 | 2020-08-25 | 北京大学 | 一种多智能体合作决策及训练方法 |
| KR102248732B1 (ko) * | 2019-06-27 | 2021-05-06 | (주)해피마인드 | 종합주의력 검사 데이터에 기초하여 주의력 결핍 및 과잉 행동 장애를 분류 및 치료반응을 예측하는 시스템 및 방법 |
| CN110313924B (zh) * | 2019-07-12 | 2022-05-17 | 中国科学院心理研究所 | 一种抗磁化无触碰式时间估计记录触发器 |
| WO2021033827A1 (ko) * | 2019-08-22 | 2021-02-25 | 주식회사 프로젝트레인보우 | 딥러닝 모듈을 이용한 발달장애 개선 시스템 및 방법 |
| US11869005B2 (en) | 2019-09-17 | 2024-01-09 | Plaid Inc. | System and method linking to accounts using credential-less authentication |
| US10722165B1 (en) * | 2019-09-30 | 2020-07-28 | BioMech Sensor LLC | Systems and methods for reaction measurement |
| WO2021064726A1 (en) * | 2019-10-02 | 2021-04-08 | Feuerstein Learning And Thinking, Ltd. | Profile oriented cognitive improvement system and method |
| US12026704B2 (en) | 2019-12-17 | 2024-07-02 | Plaid Inc. | System and method for assessing a digital interaction with a digital third party account service |
| CN111260984B (zh) * | 2020-01-20 | 2022-03-01 | 北京津发科技股份有限公司 | 多人协作的认知能力训练方法、装置及存储介质 |
| CA3189855A1 (en) | 2020-08-18 | 2022-02-24 | William Frederick Kiefer | System and method for managing user interaction flows within third party applications |
| CN112137628B (zh) * | 2020-09-10 | 2021-08-03 | 北京津发科技股份有限公司 | 三维空间认知测评及训练方法与系统 |
| CN112241971A (zh) * | 2020-09-30 | 2021-01-19 | 天津大学 | 一种使用熵和眼动数据衡量运动预测能力的方法 |
| WO2022085327A1 (ja) * | 2020-10-23 | 2022-04-28 | 株式会社島津製作所 | 脳機能解析方法および脳機能解析システム |
| CN115120240B (zh) * | 2022-08-30 | 2022-12-02 | 山东心法科技有限公司 | 特殊行业目标感知技能的敏感性评估方法、设备及介质 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2245568A4 (en) * | 2008-02-20 | 2012-12-05 | Univ Mcmaster | EXPERT SYSTEM FOR DETERMINING A PATIENT'S RESPONSE TO A TREATMENT |
| WO2010045356A1 (en) * | 2008-10-14 | 2010-04-22 | Ohio University | Cognitive and linguistic assessment using eye tracking |
| US20100292545A1 (en) * | 2009-05-14 | 2010-11-18 | Advanced Brain Monitoring, Inc. | Interactive psychophysiological profiler method and system |
| JP5476137B2 (ja) * | 2010-01-19 | 2014-04-23 | 株式会社日立製作所 | 生体および脳機能計測に基づくヒューマンインターフェイス |
| CA2720892A1 (en) * | 2010-11-12 | 2012-05-12 | The Regents Of The University Of California | Enhancing cognition in the presence of distraction and/or interruption |
| ES2831648T3 (es) * | 2010-11-24 | 2021-06-09 | Digital Artefacts Llc | Sistemas y métodos para evaluar la función cognitiva |
| WO2013111746A1 (ja) * | 2012-01-26 | 2013-08-01 | 独立行政法人国立精神・神経医療研究センター | 認知機能検査システム、認知機能推定システム、認知機能検査方法及び認知機能推定方法 |
| US9265458B2 (en) * | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| CA2949431C (en) * | 2014-05-21 | 2023-09-26 | Akili Interactive Labs, Inc. | Processor-implemented systems and methods for enhancing cognitive abilities by personalizing cognitive training regimens |
| JP6234563B2 (ja) * | 2014-05-22 | 2017-11-22 | 株式会社日立製作所 | 訓練システム |
| US20160125758A1 (en) * | 2014-10-29 | 2016-05-05 | Ohio University | Assessing cognitive function using a multi-touch device |
| JP6013438B2 (ja) | 2014-12-09 | 2016-10-25 | 株式会社Ｎｔｔデータ・アイ | 脳疾患診断支援システム、脳疾患診断支援方法及びプログラム |
-
2017
- 2017-07-19 AU AU2017299614A patent/AU2017299614A1/en not_active Abandoned
- 2017-07-19 KR KR1020197004637A patent/KR102449377B1/ko active IP Right Grant
- 2017-07-19 JP JP2019502690A patent/JP7267910B2/ja active Active
- 2017-07-19 CN CN201780057404.6A patent/CN109996485B/zh active Active
- 2017-07-19 WO PCT/US2017/042938 patent/WO2018017767A1/en unknown
- 2017-07-19 CA CA3031251A patent/CA3031251A1/en active Pending
-
2022
- 2022-06-14 JP JP2022095789A patent/JP2022153354A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190077305A (ko) | 2019-07-03 |
| CN109996485B (zh) | 2022-06-21 |
| CN109996485A (zh) | 2019-07-09 |
| AU2017299614A1 (en) | 2019-01-31 |
| WO2018017767A1 (en) | 2018-01-25 |
| JP2019528812A (ja) | 2019-10-17 |
| JP2022153354A (ja) | 2022-10-12 |
| KR102449377B1 (ko) | 2022-09-30 |
| JP7267910B2 (ja) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12016700B2 (en) | Cognitive platform coupled with a physiological component | |
| JP7473338B2 (ja) | コンピュータ化された喚起要素を含む認知プラットフォーム | |
| KR102449377B1 (ko) | 적응적 응답 기한 절차들에서의 신호 검출 메트릭들을 구현하기 위한 플랫폼들 | |
| US11846964B2 (en) | Cognitive platform including computerized elements | |
| US11839472B2 (en) | Platforms to implement signal detection metrics in adaptive response-deadline procedures | |
| US20200380882A1 (en) | Cognitive platform including computerized evocative elements in modes | |
| US20240081706A1 (en) | Platforms to implement signal detection metrics in adaptive response-deadline procedures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |
|
| EEER | Examination request |
Effective date: 20220228 |